CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Mateon Therapeutics Inc  (OXGN)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

OXGN's Income from Cont. Operations Growth by Quarter and Year

Mateon Therapeutics Inc's Income from Cont. Operations results by quarter and year




OXGN Income from Cont. Operations (in millions $) FY 2018 FY 2017 FY 2016 FY 2015
IV Quarter December - -2.43 -3.10 -3.59
III Quarter September -0.68 -3.54 -3.64 -3.32
II Quarter June -0.64 -3.88 -3.33 -2.77
I Quarter March -0.79 -3.96 -3.97 -2.64
FY   -2.11 -13.81 -14.04 -12.32



OXGN Income from Cont. Operations third quarter 2018 Y/Y Growth Comment
Mateon Therapeutics Inc in the third quarter recorded loss from continued operations of $ -0.68 millions.

According to the results reported in the third quarter, Mateon Therapeutics Inc achieved the best Income from Cont. Operations growth in Biotechnology & Drugs industry. While Mateon Therapeutics Inc' s Income from Cont. Operations no change of % ranks overall at the positon no. in the third quarter.




OXGN Income from Cont. Operations ( Y/Y Growth %) 2018
2017 2016 2015
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Mateon Therapeutics Inc's third quarter 2018 Income from Cont. Operations $ 0.00 millions OXGN's Income Statement
Mateon Therapeutics Inc's third quarter 2017 Income from Cont. Operations $ 0.00 millions Quarterly OXGN's Income Statement
New: More OXGN's historic Income from Cont. Operations Growth >>


OXGN Income from Cont. Operations (Quarter on Quarter Growth %)

2018
2017 2016 2015
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations third quarter 2018 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations third quarter 2018 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2015, 2016, 2017, 2018

Mateon Therapeutics Inc's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


OXGN's III. Quarter Q/Q Income from Cont. Operations Comment
III. Quarter 2018 loss from continued operations of -0.68 millions by Mateon Therapeutics Inc look even more unfavourable considering the -0.64 millions loss from continued operations in the previous quarter.

Within Biotechnology & Drugs industry Mateon Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Mateon Therapeutics Inc's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


OXGN's III. Quarter Q/Q Income from Cont. Operations Comment
Recent results of -0.68 millions by Mateon Therapeutics Inc appear even less good if you take a look at -0.64 millions loss from continued operations in the second quarter.

Within Biotechnology & Drugs industry Mateon Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Mateon Therapeutics Inc's Income from Cont. Operations growth quarter on quarter, overall rank is .


Mateon Therapeutics Inc's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2018)
12 Months Ending
(Jun 30 2018)
12 Months Ending
(Mar 31 2018)
12 Months Ending
(Dec 31 2017)
12 Months Ending
(Sep 30 2017)
Cumulative Income from Cont. Operations 12 Months Ending $ -4.55 $ -7.41 $ -10.65 $ -13.81 $ -14.47
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment


Mateon Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment


Mateon Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Biotechnology & Drugs Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
OXGN's Income from Cont. Operations Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for OXGN's Competitors
Income from Cont. Operations Growth for Mateon Therapeutics Inc's Suppliers
Income from Cont. Operations Growth for OXGN's Customers

You may also want to know
OXGN's Annual Growth Rates OXGN's Profitability Ratios OXGN's Asset Turnover Ratio OXGN's Dividend Growth
OXGN's Roe OXGN's Valuation Ratios OXGN's Financial Strength Ratios OXGN's Dividend Payout Ratio
OXGN's Roa OXGN's Inventory Turnover Ratio OXGN's Growth Rates OXGN's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Sep 30 2018 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Sep 30 2018
Mednax, Inc. -0.46 %$ -0.463 millions
Intuitive Surgical Inc -1.92 %$ -1.916 millions
Fonar Corporation -2.37 %$ -2.369 millions
Shire Plc -2.54 %$ -2.540 millions
Psychemedics Corp -6.52 %$ -6.525 millions
Haemonetics Corp -6.85 %$ -6.845 millions
Prestige Consumer Healthcare Inc. -7.08 %$ -7.080 millions
Amgen Inc. -8.02 %$ -8.016 millions
Eagle Pharmaceuticals, Inc. -9.01 %$ -9.014 millions
Lemaitre Vascular Inc -14.44 %$ -14.439 millions
Henry Schein Inc -15.88 %$ -15.881 millions
Standard Diversified Inc. -16.36 %$ -16.361 millions
Magellan Health Inc -18.33 %$ -18.327 millions
Conmed Corp -19.06 %$ -19.063 millions
Incyte Corp -19.08 %$ -19.077 millions
Lifepoint Health, Inc. -22.07 %$ -22.074 millions
Gilead Sciences Inc -22.60 %$ -22.603 millions
Ait Therapeutics, Inc. -37.57 %$ -37.572 millions
Emergent Biosolutions Inc. -37.57 %$ -37.573 millions
Hologic Inc -38.94 %$ -38.936 millions
Natures Sunshine Products Inc -42.97 %$ -42.973 millions
Artemis Therapeutics, Inc. -46.27 %$ -46.269 millions
Shineco, Inc. -48.52 %$ -48.520 millions
Nuvasive Inc -52.02 %$ -52.017 millions
United Therapeutics Corp -61.45 %$ -61.455 millions
Rti Surgical, Inc. -82.25 %$ -82.249 millions
Diplomat Pharmacy, Inc. -82.41 %$ -82.414 millions
Surgery Partners, Inc. -85.91 %$ -85.915 millions
Encision Inc -89.41 %$ -89.410 millions
Luminex Corp -90.14 %$ -90.138 millions


     
       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

SOAG's Profile

Stock Price

SOAG's Financials

Business Description

Fundamentals

Charts & Quotes

SOAG's News

Suppliers

SOAG's Competitors

Customers & Markets

Economic Indicators

SOAG's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Expectations

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2018 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071